Corrections:
Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
Metrics: PDF 2056 views | ?
1 Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
2 Division of Thoracic Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
3 Division of Pulmonary Medicine, Department of Internal Medicine, Chang Gung Medical Foundation Linko Branch, Taoyuan, Taiwan
4 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
5 School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan
6 Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
7 Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
8 Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
Published: July 31, 2018
This article has been corrected: The correct funding information is listed below:
This study was supported by National Science Council (NSC 102-2314-B-038-048) to PHF, Ministry of Science and Technology (MOST 103-2314-B-038 -056 and 104-2314-B-038-070) to PHF, and Taipei Medical University (TMU103- AE1-B31, TMU103-AE2-I01-3, 103TMU-SHH-01-2, 105TMU-SHH-02-2) to PHF.
Original article: Oncotarget. 2018; 9:7631-7643. DOI: https://doi.org/10.18632/oncotarget.24146.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25943